Autophagy inhibition using hydrochloroquine in breast cancer patients: a pilot study
Phase 2
Recruiting
- Conditions
- breast cancer10006291
- Registration Number
- NL-OMON34049
- Lead Sponsor
- niversitair Medisch Centrum Sint Radboud
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
•Patients with core-biopsy proven invasive adenocarcinoma of the breast
•Any tumor with a size >= 1cm (NOT inflammatory breast cancer)
•WHO-performance score 0 or 1
•Written informed consent
Exclusion Criteria
•Any psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol
•Hampered liver or kidney function
•Serious gastro-intestinal disease
•Neurological disease (including epilepsy)
•Hematological disease
•Psoriasis
•Porphyry
•G6PD deficiency
•Hypersensitivity for quinine
•Use of gold containing drugs, oxyfenbutazone, fenylbutazone, digoxin
•Operation for breast cancer foreseen within 14 days after inclusion in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>-</p><br>
- Secondary Outcome Measures
Name Time Method <p>-</p><br>